Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
188
resultados
Última actualización
14/03/2026 [06:52:00]
Resultados 25 a 50 de 188
Resumen de: US20260069664A1
Therapeutic compositions for treating a subject, the compositions including a polymeric nanoparticle, an active agent encapsulated within the polymeric nanoparticle, and a delivery vehicle for targeted delivery of the polymeric nanoparticle and encapsulated agent to a target tissue in the subject. The therapeutic compositions can be designed for targeting the destruction of a Nuclei neutrophil extracellular trap (NET) in a venous thrombus in a subject. The active agent can be an enzyme, including deoxyribonuclease 1 (DNase 1) enzyme. Methods of treating a subject using the therapeutic compositions are provided, including methods of treating venous thrombus, deep vein thrombosis, or a related blood clotting disease and/or condition.
Resumen de: US20260069549A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Resumen de: US20260069675A1
A MERS-CoV vaccine with nucleic acid sequences having at least 90% identity to the spike gene of a MERS-CoV strain as a preventive measure against MERS-CoV infections is described. The nucleic acid sequences may include plasmid DNA (pDNA) or messenger RNA (mRNA) that are encapsulated by aluminosilicates. The aluminosilicates may be functionalized with aminopropyltrimethoxysilanes.
Resumen de: US20260069542A1
The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids.
Resumen de: US20260069541A1
Disclosed herein are lipid nanoparticles for the delivery of active agents, including nucleic acids, as well as methods of making using thereof.
Resumen de: US20260069539A1
Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.
Resumen de: US20260069538A1
In various embodiments drug delivery vehicles and uses thereof are provided. In certain embodiments the drug delivery vehicles comprise: 1) a silicasome comprising a mesoporous silica nanoparticle coated with a lipid bilayer and further comprising a CXCR4 antagonist; or 2) a liposome comprising a lipid bilayer comprising where said liposome further comprises a CXCR4 antagonist. In certain embodiments the CXCR4 antagonists are selected from the group consisting of AMD3100, AMD3465, and AMD070.
Resumen de: WO2024229321A1
This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) when administered in vivo encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects.
Resumen de: WO2024228964A1
The present application, in certain aspects, pertains to methods and compositions for the treatment of cancers, such as undifferentiated pleomorphic sarcoma or leiomyosarcoma, using : (a) a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, e.g, sirolimus or a derivative thereof) and an albumin; and, optionally, (b) an anti-PD-1 antibody.
Resumen de: WO2024228632A1
The description of the invention discloses a stable polymer-lipid nanoparticle for drug binding and delivery comprising a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3- phosphocholine (DDPC), cholesterol and the ammonium salt of 1,2- distearoyl-sn-glycero-3-phosphoethanolamine-N -amino(polyethylene glycol)-2000 (DSPE-PEG(2000)NH2 and a method for producing such particles.
Resumen de: WO2024228630A1
The description of the invention discloses a composition comprising 17- AAG and staurosporine for use in the treatment of melanoma, non-small cell lung cancer, pancreatic cancer, mammary gland tumours or gliomas, and a stable polymer-lipid nanoparticle for drug binding and delivery, consisting of a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DDPC), cholesterol and the ammonium salt 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N - amino(polyethylene glycol)-2000 (DSPE-PEG(2000)NH2J.
Resumen de: AU2024263334A1
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: WO2024226779A1
The present disclosure describes lipid nanoparticle (LNP) compositions and uses thereof, e.g. for treating ocular-related disorders or diseases.
Resumen de: AU2024260092A1
The present disclosure in some aspects relates generally to nanoparticle compositions for oxygen delivery, method of use thereof, and method of preparation thereof. The present disclosure in some aspects relates generally to topical formulations capable of delivering oxygen to a tissue and methods of their use for treating diseases, such as hypoxemia.
Resumen de: EP4707386A1
The present invention provides an artificial viral capsid modified with a compound containing a fluorine atom. The artificial viral capsid is formed by self-assembly of multiple subunits, wherein the subunit comprises a β-annulus peptide of tomato bushy stunt virus, a group derived from a fluorine-containing compound, and a divalent linking group that links the β-annulus peptide to the group derived from a fluorine-containing compound; and the divalent linking group is linked to a C-terminus of the β-annulus peptide.
Resumen de: EP4706660A1
The present invention relates to a pharmaceutical composition comprising a telomerase activator and nanoparticles for drug delivery and a composition containing same for the prevention, alleviation, or treatment of hair loss. More specifically, the present invention relates to a composition effective for promoting the regeneration and growth of hair follicles, the composition being a nanoliposome, nano-liposome, nano-silica particle, or nano-bubble composition in which drugs such as the plant extract component TA-65 and a derivative thereof that increase telomerase activity, and the telomerase activating compound GPC and a derivative thereof are encapsulated
Resumen de: EP4706644A1
The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell influx rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.
Resumen de: EP4706645A1
The present invention relates to PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.
Resumen de: MX2025013065A
Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.
Resumen de: WO2024229147A2
Aspects of the disclosure relate to compositions comprising encapsulated immunotoxins and methods for using the encapsulated immunotoxins. The encapsulated immunotoxins may be capable of reaching otherwise difficult to target tissues, such as the brain, and may resist denaturation and degradation prior to reaching the targeted tissue.
Resumen de: EP4706690A1
The present application relates to the field of biological medicines, in particular to a phytic acid-based ternary complex bionic nano material. The ternary complex bionic nano material is composed of phytic acid, metal ions and a protein/polypeptide. The ternary complex is formed by connecting the protein/polypeptide with phytic acid using metal cations as a cation bridge. According to the application, the phytic acid ternary complex having different protein/polypeptide groups is synthesized by using various metal ions as bridges. A novel nano diagnosis and treatment probe having high biocompatibility is constructed, which can be reassembled and gathered for a long time at a tumor part, and has coordination-loaded imaging/therapeutic metal ions. The functions of long-acting tumor imaging, treatment or integrated diagnosis and treatment can be achieved, and the solution can be expected to be used as a novel bionic nano material in the field of biomedicine. In addition, the preparation process of the nano material is simple, and industrial production is easy to implement.
Resumen de: EP4706637A1
According to one arrangement, a drug(1) for genetic modification according to an arrangement is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule(2) and a lipid nanoparticle(3) encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane(30) having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol% or less, and the total amount of the cationic lipid is 60 mol% or less.
Resumen de: MX2025013218A
Compounds are provided having the following Structure (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R<sup>1</sup>, R<sup>1</sup>, L<sup>1</sup>, L<sup>2</sup>, L<sup>2a</sup>, L<sup>2b</sup>, and A are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: CN121622725A
本发明涉及一种环状RNA用于制备核酸药物的应用。本发明经实验研究证实，环状 RNA circPde5a 可用于制备长效减肥降糖核酸药物；将 circPde5a 递送至靶组织（如胰岛组织、白色脂肪组织）后，可通过调控靶组织代谢相关通路，实现减肥与降糖的双重效果。同时，该 circPde5a 还可与现有治疗手段协同使用。
Nº publicación: CN121622615A 10/03/2026
Solicitante:
国家纳米科学中心
Resumen de: CN121622615A
本发明属于生物技术领域，公开了一种脂质体纳米颗粒及其制备方法和应用。本发明提供的脂质体纳米颗粒的制备方法中，首先通过特定粒径的金属纳米颗粒与RNA进行共孵育，接着再取该水相溶液与包括脂质体组合物的有机相溶液进行混合，以形成具有NPs‑RNA复合内核以及脂质体外壳的核壳结构的脂质体纳米颗粒，该脂质体纳米颗粒在内体的生理条件下对于内体的膜结构具有优秀的破坏作用，能够高效地介导RNA的内体逃逸，具有良好的内体逃逸效率，以实现RNA至细胞质的高效递送，从而实现更好的治疗或免疫效果，在RNA药物和/或RNA疫苗的制备中具有巨大的应用潜力。
BOPI
Sede Electrónica
